Decan - I think you need to help me out with a bit more detail on what you meant re the CA125 reduction levels.
The way I am reading this, you are saying that PRR set themselves a target for CA125 reduction that is much lower than the "industry standard" for assessing the efficacy of an ovarian cancer diagnostic??
Is that right?
If that is so, it seems a pretty fundamental issue that goes to the credibility of the Phase IIa study??
Am I missing something??
Decan - I think you need to help me out with a bit more detail...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.3¢ |
Change
-0.003(0.75%) |
Mkt cap ! $482.9M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 33.5¢ | 33.0¢ | $57.47K | 173.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71283 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 122695 | 8 |
View Market Depth
| Last trade - 10.41am 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |